Impaired glucose tolerance and metabolic syndrome in idiopathic polyneuropathy: The role of pain and depression

Medical Hypotheses

Volumn 76, Issue 4, 2011, Pages 538-542

  Rezania, Kourosh ^a   Soliven, Betty ^a   Rezai, Kourous A ^b   Roos, Raymond P ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CATECHOLAMINE; CHOLESTEROL; CORTICOSTEROID; CREATININE; CYANOCOBALAMIN; FIBRINOGEN; GLUCOSE; GLYCOSYLATED ALBUMIN; GLYCOSYLATED HEMOGLOBIN; HEPATITIS C ANTIBODY; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CATECHOLAMINE SYNTHESIS; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CHRONIC IDIOPATHIC AXONAL POLYNEUROPATHY; CHRONIC INFLAMMATION; CHRONIC PAIN; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; IDIOPATHIC DISEASE; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KIDNEY DISEASE; MALE; METABOLIC SYNDROME X; MICROALBUMINURIA; NEUROPATHY; POLYNEUROPATHY; PROTEIN BLOOD LEVEL; RETINOPATHY; STEROIDOGENESIS; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; DEPRESSION; FEMALE; GLUCOSE INTOLERANCE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PAIN; POLYNEUROPATHIES;

EID: 79952311302     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.12.012     Document Type: Article

References (49)

1. Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample. Italian General Practitioner Study Group (IGPSG). Neurology 1995;45:1832-6.
2. Gregg EW, Sorlie P, Paulose-Ram R, Gu Q, Eberhardt MS, Wolz M, et al. Prevalence of lower-extremity disease in the US adult population 40years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care 2004;27:1591-7.
3. Dyck P.J., Oviatt K.F., Lambert E.H. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann Neurol 1981, 10:222-226.
4. Notermans N.C., Wokke J.H., Franssen H., van der Graaf Y., Vermeulen M., van den Berg L.H., et al. Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients. J Neurol Neurosurg Psychiatry 1993, 56:1066-1071.
5. Wolfe G.I., Baker N.S., Amato A.A., Jackson C.E., Nations S.P., Saperstein D.S., et al. Chronic cryptogenic sensory polyneuropathy: clinical and laboratory characteristics. Arch Neurol 1999, 56:540-547.
6. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl. 1):S5-S20.
7. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, et al. Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 2000;23:1113-8.
8. Ziegler D., Rathmann W., Dickhaus T., Meisinger C., Mielck A. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008, 31:464-469.
9. W.H. Organization, Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1: diagnosis and classification of diabetes mellitus, World Health Organization, Geneva, Switzerland; 1999.
10. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
11. Reaven G.M., Laws A. Insulin resistance: the metabolic syndrome X 1999, Humana Press, Totowa, NJ.
12. Isomaa B., Henricsson M., Almgren P., Tuomi T., Taskinen M.R., Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001, 44:1148-1154.
13. Wang X.L., Lu J.M., Pan C.Y., Tian H., Li C.L. A comparison of urinary albumin excretion rate and microalbuminuria in various glucose tolerance subjects. Diabet Med 2005, 22:332-335.
14. Costa L.A., Canani L.H., Lisboa H.R., Tres G.S., Gross J.L. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in type 2 diabetes. Diabet Med 2004, 21:252-255.
15. Russell J.W., Berent-Spillson A., Vincent A.M., Freimann C.L., Sullivan K.A., Feldman E.L. Oxidative injury and neuropathy in diabetes and impaired glucose tolerance. Neurobiol Dis 2008, 30:420-429.
16. Vincent A.M., Hayes J.M., McLean L.L., Vivekanandan-Giri A., Pennathur S., Feldman E.L. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 2009, 58:2376-2385.
17. Oltman C.L., Coppey L.J., Gellett J.S., Davidson E.P., Lund D.D., Yorek M.A. Progression of vascular and neural dysfunction in sciatic nerves of Zucker diabetic fatty and Zucker rats. Am J Physiol Endocrinol Metab 2005, 289:E113-122.
18. Singleton J.R., Smith A.G., Bromberg M.B. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001, 24:1448-1453.
19. Novella S.P., Inzucchi S.E., Goldstein J.M. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve 2001, 24:1229-1231.
20. Sumner C.J., Sheth S., Griffin J.W., Cornblath D.R., Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003, 60:108-111.
21. Hoffman-Snyder C., Smith B.E., Ross M.A., Hernandez J., Bosch E.P. Value of the oral glucose tolerance test in the evaluation of chronic idiopathic axonal polyneuropathy. Arch Neurol 2006, 63:1075-1079.
22. Nebuchennykh M., Loseth S., Jorde R., Mellgren S.I. Idiopathic polyneuropathy and impaired glucose metabolism in a Norwegian patient series. Eur J Neurol 2008, 15:810-816.
23. Hughes R.A., Umapathi T., Gray I.A., Gregson N.A., Noori M., Pannala A.S., et al. A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain 2004, 127:1723-1730.
24. Smith A.G., Rose K., Singleton J.R. Idiopathic neuropathy patients are at high risk for metabolic syndrome. J Neurol Sci 2008, 273:25-28.
25. Dyck P.J., Dyck P.J., Klein C.J., Weigand S.D. Does impaired glucose metabolism cause polyneuropathy? Review of previous studies and design of a prospective controlled population-based study. Muscle Nerve 2007, 36:536-541.
26. Greisen J., Juhl C.B., Grofte T., Vilstrup H., Jensen T.S., Schmitz O. Acute pain induces insulin resistance in humans. Anesthesiology 2001, 95:578-584.
27. Uchida I., Asoh T., Shirasaka C., Tsuji H. Effect of epidural analgesia on postoperative insulin resistance as evaluated by insulin clamp technique. Br J Surg 1988, 75:557-562.
28. Everson-Rose S.A., Meyer P.M., Powell L.H., Pandey D., Torrens J.I., Kravitz H.M., et al. Depressive symptoms, insulin resistance, and risk of diabetes in women at midlife. Diabetes Care 2004, 27:2856-2862.
29. Eaton W.W., Armenian H., Gallo J., Pratt L., Ford D.E. Depression and risk for onset of type II diabetes. A prospective population-based study. Diabetes Care 1996, 19:1097-1102.
30. Kawakami N., Takatsuka N., Shimizu H., Ishibashi H. Depressive symptoms and occurrence of type 2 diabetes among Japanese men. Diabetes Care 1999, 22:1071-1076.
31. Okamura F., Tashiro A., Utumi A., Imai T., Suchi T., Tamura D., et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000, 49:1255-1260.
32. Rosmond R., Dallman M.F., Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab 1998, 83:1853-1859.
33. Chrousos G.P., Gold P.W. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA 1992, 267:1244-1252.
34. Loevinger B.L., Muller D., Alonso C., Coe C.L. Metabolic syndrome in women with chronic pain. Metabolism 2007, 56:87-93.
35. Bierhaus A., Wolf J., Andrassy M., Rohleder N., Humpert P.M., Petrov D., et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA 2003, 100:1920-1925.
36. Black P.H. The inflammatory response is an integral part of the stress response: Implications for atherosclerosis, insulin resistance, type II diabetes and metabolic syndrome X. Brain Behav Immun 2003, 17:350-364.
37. Yudkin J.S., Juhan-Vague I., Hawe E., Humphries S.E., di Minno G., Margaglione M., et al. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 2004, 53:852-857.
38. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
39. Temelkova-Kurktschiev T., Siegert G., Bergmann S., Henkel E., Koehler C., Jaross W., et al. Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism 2002, 51:743-749.
40. Tesfaye S., Chaturvedi N., Eaton S.E., Ward J.D., Manes C., Ionescu-Tirgoviste C., et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005, 352:341-350.
41. Savage S., Estacio R.O., Jeffers B., Schrier R.W. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care 1996, 19:1243-1248.
42. Barr EL, Wong TY, Tapp RJ, Harper CA, Zimmet PZ, Atkins R, et al. Is peripheral neuropathy associated with retinopathy and albuminuria in individuals with impaired glucose metabolism? The 1999-2000 AusDiab. Diabetes Care 2006;29:1114-6.
43. Dyck P.J., Sherman W.R., Hallcher L.M., Service F.J., O'Brien P.C., Grina L.A., et al. Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry. Ann Neurol 1980, 8:590-596.
44. Ziegler D., Hanefeld M., Ruhnau K.J., Meissner H.P., Lobisch M., Schutte K., et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN study). Diabetologia 1995, 38:1425-1433.
45. Meigs J.B., Nathan D.M., Wilson P.W., Cupples L.A., Singer D.E. Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study. Ann Intern Med 1998, 128:524-533.
46. Ilanne-Parikka P., Eriksson J.G., Lindstrom J., Hamalainen H., Keinanen-Kiukaanniemi S., Laakso M., et al. Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort. Diabetes Care 2004, 27:2135-2140.
47. Metcalf P.A., Baker J.R., Scragg R.K., Dryson E., Scott A.J., Wild C.J., et al. Microalbuminuria in a middle-aged workforce. Effect of hyperglycemia and ethnicity. Diabetes Care 1993, 16:1485-1493.
48. Wong T.Y., Barr E.L., Tapp R.J., Harper C.A., Taylor H.R., Zimmet P.Z., et al. Retinopathy in persons with impaired glucose metabolism: the Australian Diabetes Obesity and Lifestyle (AusDiab) study. Am J Ophthalmol 2005, 140:1157-1159.
49. Harris M.I., Hadden W.C., Knowler W.C., Bennett P.H. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74years. Diabetes 1987, 36:523-534.